Allezoe Medical Holdings is a holding company focused on acquiring the most high-quality and in demand medical products, solutions and services that address health issues facing large populations. They are most interested in leading-edge technologies that apply proven science to offer improved outcomes and ease of use for patients, their families, and the healthcare teams that care for them.
Allezoe Medical Holdings’ subsidiary, SureScreen Medical, Inc., has signed an exclusive license to develop and market a breakthrough medical technology that will, potentially, revolutionize the diagnosis and treatment of Human Papillomavirus (HPV), Bovine Papillomavirus (BPV), and potentially cervical cancer. HPV is the most common sexually transmitted infection — there are more than 40 types — and most people who become infected do not know they have it, leading to further spread. Approximately 20 million Americans are infected with HPV and it is estimated that 5.5 million people will contract it each year. The potential impact of the SureScreen© technology is particularly important with regard to cervical cancer, the second most common cancer in women. Cervical cancer can be prevented with the right technologies and treatments. SureScreen’s© See-&-Treat© technology aims to replace the existing practice of testing a patient for HPV and requiring her to return to a healthcare provider for the results and, if necessary, treatment with a single-visit solution. Especially in third-world regions, diagnosing and treating HPV in women in a single visit can significantly raise the level of treatment and, potentially, severely reduce cervical cancer rates.
On July 19th 2012 ALZM announced that it has entered into an agreement for the merger of HealthWatch Systems, Inc., a Florida corporation, with and into HWS Acquisition Corp., a Florida corporation and wholly-owned acquisition subsidiary of ALZM. The result of the merger will be that HealthWatchSystems, Inc. (“OVWatch”) will become a wholly-owned subsidiary of ALZM and the shareholders of OVWatch, as a group, will acquire 20 percent of the outstanding stock of ALZM, post-merger, on a fully-diluted basis.
OVWatch is a privately held medical device company focused on solutions for infertility problems in couples seeking to have children. OV-Watch® is a non-invasive, wrist watch-like medical device that provides four days advance notice of ovulation to maximize conception opportunities. The product is FDA cleared (510k) is currently being marketed in the US and is also approved in Canada and Europe. The OV-Watch has been featured on The Doctor’s Show, Fox and Friends television, The Tyra Banks Show and other television and radio shows and is available on-line.
The recent acquisition of the OV-Watch technology will add another cutting-edge medical device technology to the growing line up of Allezoe Medical subsidiaries. OVWatch is a privately held medical device company focused on solutions for infertility problems in couples seeking to have children.
•OV-Watch® is a non-invasive, wrist watch-like medical device that provides four days advance notice of ovulation to maximize conception opportunities. The product is FDA cleared (510k) is currently being marketed in the US and is also approved in Canada and Europe.
•The OV-Watch has been featured on The Doctor’s Show, Fox and Friends television, The Tyra Banks Show and other television and radio shows and is available on-line.
Allezoe Medical Holdings is in the final stages of discussions to acquire a number of organizations including companies that:
•Diagnosis and treatment of Human Papillomavirus (HPV), Bovine Papillomavirus (BPV), and potentially cervical cancer. Human Papillomavirus (HPV) is the most common sexually transmitted infection. Approximately 20 million Americans are infected with HPV and it is expected that 5.5 million will contract the HPV through sexual contact each year.
•State-of-the-art implant technologies for spinal surgery
•Do clinical trial research
Let us hear your thoughts below: